Among the various immunological and non-immunological tumor-promoting activities of
myeloid-derived suppressor cells (MDSCs), their immunosuppressive capacity remains a …

Simple Summary Multiple Myeloma (MM) is a hematologic malignancy caused by aberrant
plasma cell proliferation in the bone marrow (BM) and constitutes the second most common …

Multiple myeloma (MM), a bone marrow–resident hematological malignancy of plasma cells,
has remained largely incurable despite dramatic improvements in patient outcomes in the …

It is generally accepted that metabolism is able to shape the immune response. Only
recently we are gaining awareness that the metabolic crosstalk between different tumor …

Background Lenalidomide and dexamethasone has been a standard of care in transplant-
ineligible patients with newly diagnosed multiple myeloma. The addition of a third drug to …

Over the past decades, immunotherapy has demonstrated a prominent clinical efficacy in a
wide variety of human tumors. For many years, apoptosis has been considered a non …

The clinical success of immune checkpoint inhibitors has highlighted the central role of the
immune system in cancer control. Immune checkpoint inhibitors can reinvigorate anti-cancer …

Here we show that overexpression or activation of B-cell maturation antigen (BCMA) by its
ligand, a proliferation-inducing ligand (APRIL), promotes human multiple myeloma (MM) …

Programmed cell death protein-1 (PD-1) is a checkpoint receptor expressed on the surface
of various immune cells. PD-L1, the natural receptor for PD-1, is mainly expressed in tumor …

Deregulated WNT signaling has been shown to favor malignant transformation, tumor
progression, and resistance to conventional cancer therapy in a variety of preclinical and …